SHANGHAI, May 26, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) announced that its self-developed, highly selective small molecule FGFR4 inhibitor, irpagratinib (ABSK011), has received approval of Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of...
Read More Details
Finally We wish PressBee provided you with enough information of ( Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC )
Also on site :
- Stocks rally and oil dips after report says Iran is looking to de-escalate its conflict with Israel
- Oil prices up after reports of 3 ships on fire in Gulf of Oman near the strait of Hormuz
- 'Days of Our Lives' Mary Beth Evans Honors 'Legend' Stephen Nichols on 40th Anniversary: "What a Ride'